Drug intelligence / Profile preview

SP029

Development stage: Preclinical
Lead developer: Y Biologics

Overview

SP029 is a preclinical-stage therapeutic candidate being developed by Y Biologics for the treatment of solid tumors. The drug was identified or designed using artificial intelligence (AI) discovery platforms. As of current pipeline reports, the specific biological target, molecular structure, and precise mechanism of action remain undisclosed by Y Biologics. It represents the company's efforts to integrate AI into its biologics-focused pipeline to identify novel candidates for oncology indications.

Beyond the preview

Go deeper on SP029.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP029.

Explore the full profile